Related Experiment Video
Updated: Mar 23, 2026
Author Spotlight: Establishing CENP-E Knockout HeLa Cells – A Novel Approach to Study Kinesin-7 CENP-E Biology and its Inhibitors
Published on: June 23, 2023
Lifting Up the HAT: Synthetic Lethal Screening Reveals a Novel Vulnerability at the CBP-p300 Axis
1Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. Broad Institute of MIT and Harvard, Cambridge, Massachusetts. Cigall_kadoch@dfci.harvard.edu.
Abstract:
Cancer genotype-specific synthetic lethal vulnerabilities represent promising therapeutic targets. In this issue of Cancer Discovery, Ogiwara and colleagues uncover a synthetic lethal relationship between two histone acetyl transferase paralogs, CBP and p300, highlighting that cancer cells deficient in CBP are uniquely sensitized to genetic and chemical inhibition of p300.
Insights
Cancer cells lacking CBP are vulnerable to p300 inhibition. This discovery reveals a synthetic lethal interaction between CBP and p300, offering new therapeutic targets for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Synthetic lethality offers targeted cancer therapy strategies.
- Histone acetyltransferases CBP and p300 are epigenetic regulators implicated in various cancers.
Purpose of the Study:
- To investigate the synthetic lethal relationship between CBP and p300 in cancer cells.
- To identify genotype-specific vulnerabilities for targeted cancer therapies.
Main Methods:
- Utilized genetic and chemical inhibition of CBP and p300.
- Assessed cancer cell viability and sensitivity to p300 inhibition in CBP-deficient contexts.
Main Results:
- Discovered a synthetic lethal interaction between CBP and p300.
- Cancer cells deficient in CBP exhibit heightened sensitivity to p300 inhibition, both genetically and chemically.
Conclusions:
- CBP deficiency creates a synthetic lethal vulnerability exploitable by targeting p300.
- This finding provides a basis for developing novel p300-targeted therapies for CBP-altered cancers.
